How Can We Help?
Skip to content
Researcher looking at a book

2020 FDA Draft Guidance, “Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry”

  • Published on August 25, 2020
  • Biologics & Oligonucleotides
  • Drug Drug Interactions (DDI)
  • Regulatory Guidance
  • Regulatory Documents

In August 2020, the FDA released the draft guidance for industry to evaluate therapeutic proteins for drug-drug interaction (DDI) potential using a risk-based approach.

“The purpose of this guidance is to help sponsors of investigational new drug applications (INDs) and applicants of biologic license applications (BLAs) determine the need for drug-drug
interaction (DDI) studies for a therapeutic protein (TP) by providing a systematic, risk-based approach. ”

Download Publication